Patient-specific dose finding in seamless phase I/II clinical trials

DOI10.1080/07474946.2022.2105361MaRDI QIDQ5043686zbMATH OpenOpenAlexFDO

Authors M. Iftakhar Alam, Shantonu Islam Shanto

Publication date 6 October 2022

Published in Sequential Analysis (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/07474946.2022.2105361

zbMATH Keywords

dose-finding studydose-response modeloptimum dosepatients' heterogeneityseamless phase I/II trial

Mathematics Subject Classification ID

Design of statistical experiments (62K99) Sequential statistical design (62L05) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• Biometric practicesimple benchmark for complex dose finding studies
• Dose-finding designs for HIV studies
• Dose-Response Models with Covariates
• scientific article; zbMATH DE number 47310 (Why is no real title available?)
• Individualized dosing for multiple ordered groups of patients
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates

Cited in

(4)

• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets
• Dose individualization for phase I cancer trials with broadened eligibility

This page was built for publication: Patient-specific dose finding in seamless phase I/II clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5043686)